Taking tesamorelin for a year makes IGF-I levels rise much more in obese people with low growth hormone than taking a dummy pill, with a clear difference between the two groups.
Scientific Claim
Twelve months of tesamorelin treatment in obese adults with reduced growth hormone secretion results in a significantly greater increase in insulin-like growth factor I (IGF-I) levels (102.9 ± 31.8 μg/L) compared to placebo (22.8 ± 8.9 μg/L), with a p-value of 0.02.
Original Statement
“After 12 months, tesamorelin treatment led to a significantly greater increase in IGF-I than did placebo treatment (change, 102.9±31.8 μg/L vs 22.8±8.9 μg/L, tesamorelin vs placebo; P=.02).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
As a randomized controlled trial, this study design supports causal claims. The language 'results in a significantly greater increase' accurately reflects the causal relationship demonstrated by the data.
Evidence from Studies
Supporting (1)
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.